An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
An evaluation finds pembrolizumab with trastuzumab and chemotherapy improves outcomes for HER2-positive gastric adenocarcinoma, suggesting further advancements are necessary.
Key Points
This research aims to evaluate the effectiveness of pembrolizumab combined with trastuzumab and chemotherapy for treating HER2-positive gastric cancer expressing PD-L1.
Assessment of treatment outcomes in patients with HER2-positive gastric adenocarcinoma
Analysis of primary and acquired resistance factors
Discussion of next-generation HER2-targeted therapies
Pembrolizumab plus trastuzumab and chemotherapy establishes a new standard of care
Resistance due to HER2 heterogeneity and immune evasion remains a challenge
Next-generation therapies such as bispecific antibodies and novel drug-conjugates are necessary for improved outcomes.